1. A 10‐year single‐institution retrospective review of treatment for acquired hemophilia A.
- Author
-
Wu, James F., Malec, Lynn M., Pandit, Sarbagya, Abid, Haisam, Jha, Pinky, and Baumann Kreuziger, Lisa M.
- Subjects
- *
HEMOPHILIA treatment , *BLOOD coagulation factor VIII , *HEMOPHILIACS , *RETROSPECTIVE studies , *RITUXIMAB - Abstract
This article discusses the treatment and outcomes of patients with acquired hemophilia A (AHA) at a single center. The study found that the implementation of a treatment algorithm standardized care and improved outcomes for patients. The use of recombinant porcine factor VIII (rpFVIII) as the first-line hemostatic agent and rituximab as a treatment option increased. The study also found that outpatient treatment with hemostatic agents was feasible and allowed for reimbursement. The study acknowledges its limitations, including its small sample size and retrospective design. Overall, the findings suggest that the treatment algorithm improved the management of AHA patients at the center. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF